tiprankstipranks
Advertisement
Advertisement

TARS Stock Latest News

Tarsus Pharmaceuticals: Buy Rating Backed by Capital-Efficient IRX-101 Acquisition and High-Margin Retina Market Opportunity
RatingsTarsus Pharmaceuticals: Buy Rating Backed by Capital-Efficient IRX-101 Acquisition and High-Margin Retina Market Opportunity
2d ago
TARS
Tarsus Pharmaceuticals Acquires iRenix to Expand Retinal Care
PremiumCompany Announcements
Tarsus Pharmaceuticals Acquires iRenix to Expand Retinal Care
2d ago
8K
TARS
Tarsus Pharmaceuticals acquires iRenix Medical
PremiumThe Fly
Tarsus Pharmaceuticals acquires iRenix Medical
2d ago
TARS
Culper Research announces Tarsus Pharmaceuticals short position
PremiumThe Fly
Culper Research announces Tarsus Pharmaceuticals short position
10d ago
TARS
Tarsus drops 10% to $57.08 after Culper announces short position
PremiumThe Fly
Tarsus drops 10% to $57.08 after Culper announces short position
10d ago
TARS
Tarsus Pharmaceuticals Stockholders Approve Governance and Oversight
PremiumCompany AnnouncementsTarsus Pharmaceuticals Stockholders Approve Governance and Oversight
11d ago
8K
TARS
Tarsus Advances TP-05 Lyme Prevention Trial, Setting Up a New Mid-Stage Catalyst for TARS Investors
Premium
Company Announcements
Tarsus Advances TP-05 Lyme Prevention Trial, Setting Up a New Mid-Stage Catalyst for TARS Investors
2M ago
TARS
Tarsus Pharmaceuticals Earnings Call Signals Durable Growth
Premium
Company Announcements
Tarsus Pharmaceuticals Earnings Call Signals Durable Growth
2M ago
TARS
Tarsus Pharmaceuticals reports Q1 EPS (16c), consensus (40c)
PremiumThe Fly
Tarsus Pharmaceuticals reports Q1 EPS (16c), consensus (40c)
2M ago
TARS
3 Best Growth Stocks to Buy in May 2026, According to Analysts
PremiumMarket News
3 Best Growth Stocks to Buy in May 2026, According to Analysts
2M ago
NFLX
PANW
Buy Rating Reaffirmed on XDEMVY as Inventory Dynamics Seen as Transient and $88 Price Target Remains Unchanged
PremiumRatings
Buy Rating Reaffirmed on XDEMVY as Inventory Dynamics Seen as Transient and $88 Price Target Remains Unchanged
2M ago
TARS
Tarsus Pharmaceuticals assumed with an Outperform at Oppenheimer
PremiumThe Fly
Tarsus Pharmaceuticals assumed with an Outperform at Oppenheimer
3M ago
TARS
Buy Rating Backed by Blockbuster Xdemvy Launch and TP-05 Lyme Prevention Opportunity
PremiumRatingsBuy Rating Backed by Blockbuster Xdemvy Launch and TP-05 Lyme Prevention Opportunity
3M ago
TARS
Tarsus Pharmaceuticals doses first participant in TP-05 trial
Premium
The Fly
Tarsus Pharmaceuticals doses first participant in TP-05 trial
3M ago
TARS
Tarsus Pharmaceuticals price target raised to $101 from $100 at Mizuho
Premium
The Fly
Tarsus Pharmaceuticals price target raised to $101 from $100 at Mizuho
4M ago
TARS
Tarsus Pharmaceuticals to receive $15M milestone on China TP-03 approval
PremiumThe Fly
Tarsus Pharmaceuticals to receive $15M milestone on China TP-03 approval
4M ago
TARS
Tarsus Pharmaceuticals Bets Big on XDEMVY Growth
PremiumCompany Announcements
Tarsus Pharmaceuticals Bets Big on XDEMVY Growth
4M ago
TARS
Tarsus Pharmaceuticals price target raised to $105 from $95 at Oppenheimer
PremiumThe Fly
Tarsus Pharmaceuticals price target raised to $105 from $95 at Oppenheimer
5M ago
TARS
Tarsus Pharmaceuticals price target raised to $90 from $87 at Guggenheim
PremiumThe Fly
Tarsus Pharmaceuticals price target raised to $90 from $87 at Guggenheim
5M ago
TARS
Tarsus Pharmaceuticals rises 11.6%
PremiumThe FlyTarsus Pharmaceuticals rises 11.6%
5M ago
TARS
Tarsus Pharmaceuticals price target raised to $90 from $88 at BofA
Premium
The Fly
Tarsus Pharmaceuticals price target raised to $90 from $88 at BofA
5M ago
TARS
Sustained Growth Outlook for Tarsus Driven by XDEMVY’s Rapid Ramp and Expanding Lotilaner Pipeline
Premium
Ratings
Sustained Growth Outlook for Tarsus Driven by XDEMVY’s Rapid Ramp and Expanding Lotilaner Pipeline
5M ago
TARS

Trending

Name
Price
Price Change
SPX
S&P 500
―
DJIA
Dow Jones
―
NDX
Nasdaq 100
―
More Trending Stocks >